Published in J Immunol on October 01, 2002
Peptide antimicrobial agents. Clin Microbiol Rev (2006) 6.04
Contribution of neutrophils to acute lung injury. Mol Med (2010) 3.59
Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol (2008) 2.70
Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe (2010) 2.39
Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol (2007) 2.10
Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros (2007) 2.07
Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother (2005) 1.67
Alarmins link neutrophils and dendritic cells. Trends Immunol (2009) 1.61
The roles of antimicrobial peptides in innate host defense. Curr Pharm Des (2009) 1.58
Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res (2005) 1.58
Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol (2005) 1.55
Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One (2011) 1.39
Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun (2007) 1.38
Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol (2004) 1.33
Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother (2005) 1.28
Human β-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF. Eur J Immunol (2011) 1.27
Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother (2005) 1.27
Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol (2010) 1.26
The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol (2006) 1.25
Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun (2005) 1.24
Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J Immunol (2012) 1.20
Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res (2008) 1.19
Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res (2006) 1.18
Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol (2010) 1.15
Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol (2013) 1.15
Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur J Immunol (2009) 1.14
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol (2010) 1.12
Host defense peptides in wound healing. Mol Med (2008) 1.10
Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int J Mol Sci (2009) 1.08
Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys J (2011) 1.08
Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys J (2010) 1.06
Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One (2012) 1.06
A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J Exp Med (2006) 1.06
NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. J Biol Chem (2009) 1.05
Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol (2005) 1.02
Defensins and other antimicrobial peptides at the ocular surface. Ocul Surf (2004) 1.00
Toll-like receptor activation modulates antimicrobial peptide expression by ocular surface cells. Exp Eye Res (2010) 1.00
Vitamin D-mediated induction of innate immunity in gingival epithelial cells. Infect Immun (2011) 0.99
Peptide design for antimicrobial and immunomodulatory applications. Biopolymers (2013) 0.99
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Defensins: antifungal lessons from eukaryotes. Front Microbiol (2014) 0.99
Endotoxin, capsule, and bacterial attachment contribute to Neisseria meningitidis resistance to the human antimicrobial peptide LL-37. J Bacteriol (2009) 0.97
Neutrophil secondary necrosis is induced by LL-37 derived from cathelicidin. J Leukoc Biol (2008) 0.96
Activity of mesenchymal stem cells in therapies for chronic skin wound healing. Organogenesis (2013) 0.96
Histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and alters HagB-induced chemokine responses. Sci Rep (2014) 0.96
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One (2011) 0.95
NF-kappaB-dependent induction of cathelicidin-related antimicrobial peptide in murine mast cells by lipopolysaccharide. Int Arch Allergy Immunol (2009) 0.94
Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob Agents Chemother (2006) 0.94
Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS One (2015) 0.93
The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacol Physiol (2012) 0.93
Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages. J Leukoc Biol (2009) 0.93
Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J (2009) 0.93
Epithelial cell-derived antimicrobial peptides are multifunctional agents that bridge innate and adaptive immunity. Periodontol 2000 (2010) 0.92
Cathelicidin peptide LL-37 modulates TREM-1 expression and inflammatory responses to microbial compounds. Inflammation (2011) 0.92
Cationic host defence peptides: potential as antiviral therapeutics. BioDrugs (2013) 0.92
Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. Antimicrob Agents Chemother (2014) 0.91
New therapeutic approaches for treatment of tularaemia: a review. Front Cell Infect Microbiol (2014) 0.91
Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes. J Invest Dermatol (2005) 0.90
Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL-37 treated monocytes. PLoS One (2010) 0.89
Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering. Curr Opin Solid State Mater Sci (2013) 0.89
Multiple immune-modulatory functions of cathelicidin host defense peptides. Front Immunol (2012) 0.88
LPS inmobilization on porous and non-porous supports as an approach for the isolation of anti-LPS host-defense peptides. Front Microbiol (2013) 0.88
The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One (2013) 0.88
Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS One (2014) 0.88
DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat (2013) 0.87
Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis. J Infect Dis (2014) 0.87
LL-37 secreted by epithelium promotes fibroblast collagen production: a potential mechanism of small airway remodeling in chronic obstructive pulmonary disease. Lab Invest (2014) 0.87
Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-induced sepsis. J Immunol (2014) 0.86
Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease. J Invest Dermatol (2011) 0.85
Modulation of the immune response to respiratory viruses by vitamin D. Nutrients (2015) 0.85
Peptides and Peptidomimetics for Antimicrobial Drug Design. Pharmaceuticals (Basel) (2015) 0.85
Saliva enables the antimicrobial activity of LL-37 in the presence of proteases of Porphyromonas gingivalis. Infect Immun (2009) 0.84
Effect of vitamin D supplementation on Mycobacterium tuberculosis-induced innate immune responses in a Canadian Dené First Nations cohort. PLoS One (2012) 0.83
Vitamin D status is not associated with inflammatory cytokine levels during experimental human endotoxaemia. Clin Exp Immunol (2013) 0.83
A potential wound-healing-promoting peptide from salamander skin. FASEB J (2014) 0.82
Immune-epithelial crosstalk at the intestinal surface. J Gastroenterol (2014) 0.81
Additive effects of orexin B and vasoactive intestinal polypeptide on LL-37-mediated antimicrobial activities. J Neuroimmunol (2010) 0.81
2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. J Leukoc Biol (2012) 0.81
Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur J Nutr (2012) 0.81
Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2. PLoS One (2011) 0.81
The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz) (2015) 0.81
Nuclear localization of HBD-1 in human keratinocytes. J Burns Wounds (2007) 0.80
Prevention of death in bacterium-infected mice by a synthetic antimicrobial peptide, L5, through activation of host immunity. Antimicrob Agents Chemother (2009) 0.80
Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans. J Immunol (2016) 0.80
NKLP27: a teleost NK-lysin peptide that modulates immune response, induces degradation of bacterial DNA, and inhibits bacterial and viral infection. PLoS One (2014) 0.80
Cathelicidin impact on inflammatory cells. Cent Eur J Immunol (2015) 0.79
LL-37 modulates human neutrophil responses to influenza A virus. J Leukoc Biol (2014) 0.79
Defensins and LL-37: a review of function in the gingival epithelium. Periodontol 2000 (2013) 0.79
Episodic binge ethanol exposure impairs murine macrophage infiltration and delays wound closure by promoting defects in early innate immune responses. Alcohol Clin Exp Res (2014) 0.79
Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders. Acta Pharmacol Sin (2010) 0.79
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol (2016) 0.79
Non-coding Double-stranded RNA and Antimicrobial Peptide LL-37 Induce Growth Factor Expression from Keratinocytes and Endothelial Cells. J Biol Chem (2016) 0.78
Therapeutic approaches using host defence peptides to tackle herpes virus infections. Viruses (2009) 0.78
Immunomodulatory and Anti-Inflammatory Activities of Chicken Cathelicidin-2 Derived Peptides. PLoS One (2016) 0.78
Antimicrobial peptide scolopendrasin VII, derived from the centipede Scolopendra subspinipes mutilans, stimulates macrophage chemotaxis via formyl peptide receptor 1. BMB Rep (2015) 0.78
Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun (2012) 0.78
Host Antimicrobial Peptides in Bacterial Homeostasis and Pathogenesis of Disease. Antibiotics (Basel) (2014) 0.78
Interspecies cathelicidin comparison reveals divergence in antimicrobial activity, TLR modulation, chemokine induction and regulation of phagocytosis. Sci Rep (2017) 0.77
Cathelicidins from the bullfrog Rana catesbeiana provides novel template for peptide antibiotic design. PLoS One (2014) 0.77
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc (2008) 7.92
Peptide antimicrobial agents. Clin Microbiol Rev (2006) 6.04
Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res (2010) 5.23
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol (2008) 5.09
PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods (2011) 5.01
Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell (2002) 4.94
InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol Syst Biol (2008) 4.61
Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov (2011) 4.16
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol (2010) 3.56
Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol (2011) 3.49
Cerebral: a Cytoscape plugin for layout of and interaction with biological networks using subcellular localization annotation. Bioinformatics (2007) 3.39
Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. Nat Methods (2012) 3.17
Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation (2013) 3.14
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol (2003) 3.06
Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res (2008) 3.03
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol (2007) 2.90
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation. Am J Respir Crit Care Med (2013) 2.71
Pseudomonas Genome Database: facilitating user-friendly, comprehensive comparisons of microbial genomes. Nucleic Acids Res (2008) 2.71
Cationic host defense (antimicrobial) peptides. Curr Opin Immunol (2005) 2.71
InnateDB: systems biology of innate immunity and beyond--recent updates and continuing curation. Nucleic Acids Res (2012) 2.66
Pseudomonas aeruginosa Genome Database and PseudoCAP: facilitating community-based, continually updated, genome annotation. Nucleic Acids Res (2005) 2.61
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol (2004) 2.51
The relationship between peptide structure and antibacterial activity. Peptides (2003) 2.51
Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med (2002) 2.40
Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta (2006) 2.35
Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol (2006) 2.32
Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis (2013) 2.32
Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem (2005) 2.28
Construction of a mini-Tn5-luxCDABE mutant library in Pseudomonas aeruginosa PAO1: a tool for identifying differentially regulated genes. Genome Res (2005) 2.22
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation (2009) 2.10
Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion. Nat Protoc (2007) 2.08
Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther (2007) 2.06
ArrayPipe: a flexible processing pipeline for microarray data. Nucleic Acids Res (2004) 2.03
High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol (2005) 2.01
Impact of LL-37 on anti-infective immunity. J Leukoc Biol (2004) 2.01
Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci (2011) 1.99
Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. J Bacteriol (2008) 1.98
An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol (2007) 1.97
Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm (2010) 1.92
The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol (2009) 1.92
Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev (2009) 1.91
Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun (2008) 1.91
Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol (2004) 1.90
Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia. Thorax (2009) 1.87
Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem Biol (2006) 1.84
Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.82
Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury. Am J Respir Crit Care Med (2012) 1.82
The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol (2004) 1.78
The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother (2011) 1.78
A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci (2005) 1.78
Genome-wide identification of Pseudomonas aeruginosa exported proteins using a consensus computational strategy combined with a laboratory-based PhoA fusion screen. Genome Res (2005) 1.77
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother (2010) 1.74
Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev (2012) 1.74
Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today (2005) 1.74
Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol (2013) 1.73
Evidence that plant-like genes in Chlamydia species reflect an ancestral relationship between Chlamydiaceae, cyanobacteria, and the chloroplast. Genome Res (2002) 1.72
Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother (2002) 1.69
Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother (2005) 1.67
Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrob Agents Chemother (2008) 1.67
Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol (2011) 1.65
Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol (2013) 1.63
Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother (2012) 1.63
Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS One (2009) 1.61
AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics (2007) 1.59
Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob Agents Chemother (2003) 1.59
Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol (2009) 1.58
Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation (2002) 1.58
Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol (2002) 1.58
Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J (2013) 1.55
Identification of genes involved in swarming motility using a Pseudomonas aeruginosa PAO1 mini-Tn5-lux mutant library. J Bacteriol (2006) 1.54
Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides. Biopolymers (2008) 1.51
Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol (2004) 1.51
Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol (2013) 1.51
The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) (2007) 1.50
Characterization of a proteolytically stable multifunctional host defense peptidomimetic. Chem Biol (2013) 1.49
Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine (2011) 1.48
INMEX--a web-based tool for integrative meta-analysis of expression data. Nucleic Acids Res (2013) 1.48
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J (2013) 1.45
Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. J Cardiovasc Electrophysiol (2006) 1.44
Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Chemother (2005) 1.44
ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J (2006) 1.44
The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol (2004) 1.41
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J (2012) 1.41
Improved defibrillation efficacy with an ascending ramp waveform in humans. Heart Rhythm (2005) 1.40
Postentrainment activation sequence: diagnostic of the supraventricular tachycardia mechanism? J Cardiovasc Electrophysiol (2002) 1.40
Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One (2011) 1.39
Cardiac resynchronization therapy for mild heart failure: the time has come. Circulation (2011) 1.39
Intracellular receptor for human host defense peptide LL-37 in monocytes. J Immunol (2009) 1.38